Eisai: Strong revenue and profit growth driven by key products and new market launches
I'm LongbridgeAI, I can summarize articles.Revenue and profit rose sharply year-over-year, led by strong sales of Lenvima, Leqembi, and Dayvigo, and supported by favorable currency effects. FY2026 guidance remains unchanged, with robust growth expected across all major segments.Original document: Eisai Co., Ltd. [4523] Interim report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue and profit rose sharply year-over-year, led by strong sales of Lenvima, Leqembi, and Dayvigo, and supported by favorable currency effects. FY2026 guidance remains unchanged, with robust growth expected across all major segments.
Original document: Eisai Co., Ltd. [4523] Interim report — Aug. 3 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.